Advanced or Metastatic Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.
This study will consist of two treatment arms (Groups A and B). Participants will be randomised in a 1:1 ratio to one of the two treatment groups: - Group A: Ceralasertib plus durvalumab combination therapy Each 28-day cycle will begin with ceralasertib administered orally followed by durvalumab administered intravenously. - Group B: Docetaxel monotherapy Each 21-day cycle will begin with the administration of docetaxel. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05621525 -
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
|
Phase 1 | |
| Completed |
NCT00716534 -
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Active, not recruiting |
NCT05388669 -
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT02855125 -
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
|
Phase 2 |